Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
GHK-Cu is a small peptide bound to copper that occurs naturally in human blood; it is sold in skin serums and creams and as an injection, and promoted for younger-looking skin, hair growth and wound repair. The strongest evidence is for products put on the skin: tested in people, one maker-funded trial of 40 women found smaller wrinkles after eight weeks of a GHK-Cu serum than on the comparison side of the face, a trial that 13 people completed after laser treatment found no difference on its evaluators’ measures, and two wound trials point in opposite directions. Injected GHK-Cu has not been tested in people: no study of it on its own was found, so neither its benefit nor its safety by injection has been measured.
Skin use and injection are separate questions, kept apart throughout this review, which is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. For non-injectable forms only, the FDA says it doesn’t intend to act against compounders, under conditions.
- Evidence in people
- On the skin: five randomized trials, with mixed results. Injected on its own: no study in people was found.
- The claim you’ve heard
- A serum softens fine lines: supported in people, weakly. Injections work better: not tested in people.
- Doses tested in people
- Skin products only, for example a 2% serum. None for GHK-Cu alone by injection.
- Sport
- Not named on WADA’s 2026 or 2027 Prohibited List. WADA cautions that an unnamed peptide “may still be prohibited”.
What GHK-Cu is
GHK-Cu is three amino acids (glycine, histidine and lysine: the “GHK”) holding one copper ion (the “Cu”). Cosmetic labels call it copper tripeptide-1; it also goes by prezatide copper, or “copper peptide”. Without its copper, the peptide is GHK.
It is a natural human peptide, reported in human serum in 1973 and identified in 1977. What is sold is synthetic.
It has reached people in four forms:
- On the skin, as a cosmetic. Copper-peptide serums and creams have been sold for decades.
- On wounds, as a medical device. A copper-peptide wound gel, Iamin Gel from ProCyte Corporation, was cleared by the FDA as a wound dressing in 1996. A device clearance is not drug approval.
- By injection. Compounded products and products sold online are injected alone or in blends: “GLOW” (GHK-Cu with BPC-157 and TB-500) and “KLOW” (the same plus KPV). No study of either blend was found.
- By mouth. An oral liquid is sold online. No data were found on whether swallowed GHK-Cu is absorbed.
Two look-alikes are different molecules, and studies of them are not evidence about GHK-Cu: palmitoyl tripeptide-1 (Pal-GHK), used in anti-wrinkle products, has no copper and carries a fatty-acid tail; AHK-Cu has alanine in place of glycine.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: no form of GHK-Cu is an FDA-approved medicine. For forms that are not injected, the FDA says it does not intend to act against compounders, under conditions, while it evaluates the substance; injectable GHK-Cu is outside that policy, and the FDA has stated a safety concern about it.
As of November 19, 2026, GHK-Cu is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. For non-injectable forms, the FDA lists “GHK-Cu (except for injectable routes of administration)” in Category 1 of its interim compounding policy, under which the FDA “does not intend to take action against a compounder” if the policy’s conditions are met; injectable GHK-Cu is in no category, and the FDA says compounded injectable GHK-Cu “may pose risk for immunogenicity”. The FDA plans to consult its advisory committee on GHK-Cu before the end of February 2027.
Non-injectable forms
Category 1 holds substances the FDA is still evaluating; it is not a finding that one is safe or that it works. The FDA describes Category 1 substances as ones that “cannot otherwise be used under section 503A” [the federal law on compounding a medicine for one patient], and it can remove one “based on, for example, information about safety risks.”
Kansas, where we practice, has its own rule. K.A.R. 68-13-3(d) says a pharmacist “shall not compound a nonsterile preparation” [a cream or gel, for example] by “compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs”, and it reaches preparations shipped into Kansas. The Kansas Board of Pharmacy has published nothing on how it applies the rule to GHK-Cu.
Injectable GHK-Cu
The FDA lists “GHK-Cu (for injectable routes of administration)” among substances whose nominations were withdrawn, and says: “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.” [Immunogenicity: provoking an immune reaction. Aggregation: peptide molecules clumping together.] Its guidance says a drug compounded from a substance that meets none of section 503A’s three conditions “is not eligible for the exemptions in section 503A and may violate the FD&C Act” [the federal food and drug law]. In April 2020 it warned a compounding pharmacy that had “compounded drug products using … GHK-Cu” and other peptides not eligible for those exemptions.
HHS’s draft policy
GHK-Cu is not among the six peptides named in the draft interim policy that HHS, the federal department the FDA belongs to, announced on October 30, 2026. HHS said it “does not intend to take enforcement action” when the policy’s conditions are met; one is that “the compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”, so an injectable blend containing GHK-Cu is outside that policy as well.
Cosmetic or drug
The FDA says: “Whether a product is a cosmetic or a drug under the law is determined by a product’s intended use.” Cosmetics “do not require FDA approval before they go on the market”, so a copper-peptide serum sold only for appearance is regulated as a cosmetic. A claim that a product will “restore hair growth … or regenerate cells” makes it a drug under that test.
Sport
GHK-Cu is not named on WADA’s Prohibited List for 2026 or 2027, and WADA has not said whether it treats it under the List’s S0 class, which covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”. WADA’s note on the 2027 List says: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
Claims you’ll see, and why sources disagree
Pages disagree mainly for four reasons:
- Skin results are read as injection results. High-ranking pages present injections as routine, with schedules and mild side effects; the trials in people were of products put on the skin.
- Cell results are read as human results. The “4,000 genes” claims trace to re-analyses of three gene-activity profiles in a public database, made in two cancer cell lines.
- Other molecules get counted. The often-cited lab study of human hair follicles used AHK-Cu; the scalp studies in people used mixtures or a copper-free GHK compound.
- The most-read summaries share one author. They are reviews by Pickart, who isolated the peptide. They give as his affiliation a skin-care company that sells copper-peptide products under his name; the 2015 and 2018 reviews declare no conflict of interest.
“Not tested in people” is not the same as “doesn’t work”. It cuts both ways: an untested use has not been shown to help, or to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| A GHK-Cu serum or cream softens fine lines | Tested in people: one maker-funded trial found an effect; in a very small one, evaluators found none | Supported in people, weakly |
| It makes skin produce collagen and elastin | Lab studies (cells) and animal studies (rat wounds); in people, only biopsies after a five-ingredient solution | Not tested in people for GHK-Cu alone |
| It supports hair growth and reduces gray hair | Tested in people once (a serum on the eyebrows of 18 people). Scalp studies used mixtures or other molecules; nothing found on gray hair | Not tested alone for scalp hair loss |
| It speeds the repair of wounds and of skin after laser | Tested in people on the skin, mixed: one ulcer trial positive, one negative; after laser, no benefit on evaluators’ measures | Mixed; not established |
| It resets hundreds or thousands of genes | Lab studies: computer analysis of cancer cell-line data | Not tested in people |
| It lowers oxidative stress and inflammation | Animal studies (mouse lung) and lab studies | Not tested in people |
| Injection works better than a cream, on a “typical” schedule | None: no study in people, and no tested dose, of injected GHK-Cu alone | Not tested; the schedules are conventions no study set |
| Injections cause only mild reactions | None for GHK-Cu alone. Reported in people for mixtures given by needle: “well tolerated” (1,000 patients); no adverse reactions (7 men) | Not established; the FDA has stated a safety concern |
What the evidence consists of
The human record comes from PubMed (more than 400 titles screened) and ClinicalTrials.gov, cross-checked against two 2026 reviews (in Pharmaceutics and Aesthetic Surgery Journal).
Tested in people: on the skin
Five randomized trials have tested a copper-peptide product on the skin.
| Study | People | Design and what was given | What happened | Funding or limits |
|---|---|---|---|---|
| Bishop, 1992 | 86 evaluable patients with venous stasis ulcers | Evaluator-blinded: a tripeptide-copper cream, silver sulfadiazine cream or an inert cream | Silver sulfadiazine reduced ulcer size. Between the copper cream and the inert cream, “There was no difference”. | Abstract only; funder not in it. The tripeptide is not named; reading it as GHK-Cu is an inference. |
| Mulder, 1994 | Diabetic foot ulcers; number not in the abstract | Multicentre, evaluator-blinded: a copper-peptide gel (Iamin Gel) or its base, with standard care | Median closure of ulcer area 98.5% with the gel, 60.8% with the base (p < 0.05). | Abstract only: size, dropouts and sponsor unknown. The gel was ProCyte’s product. |
| Miller, 2006 | 13 who completed, after laser resurfacing around the mouth | Blinded evaluators: skin-care products with or without GHK-Cu, 12 weeks | No significant difference in redness, wrinkles or skin quality. A patient questionnaire favoured GHK-Cu (P = .04). | Abstract only; funder not in it. Very small; product not defined. |
| Badenhorst, 2016 | 40 women aged 40 to 65; one stopped | Double-blind, split-face, 8 weeks: a GHK-Cu serum in a lipid nano-carrier against the serum base (20 women) or a different peptide product (19) | Against the base: wrinkle volume “55.8% relative reduction” (p<0.01), depth “32.8% decrease” (p=0.0123). Against the other product: volume reduced 31.6% more (p<0.01); depth not significantly different (p=0.0577). | Funded by the serum’s maker, which the paper says “had no involvement in the collection, analysis, interpretation of data”. The base had neither GHK-Cu nor carrier. One wrinkle per person. Not found in PubMed. |
| Bo, 2026 | 18 adults aged 18 to 40 with sparse eyebrows | Double-blind, split-face, 12 weeks: a GHK-Cu serum on one eyebrow, its base on the other | At week 12 the treated side had a mean of 1.833 (± 0.864) more hairs than the placebo side (p = 0.049); no difference at weeks 4 and 8. Hair diameter (units not stated) and a score called GPAS also favoured it (p = 0.036, p = 0.010). | Proceedings paper; funding not stated; no conflict declared. Four time points, no adjustment stated. Patch-test reactors excluded. |
Use by use:
- Wrinkles. One trial found an effect, and the evaluators in one very small trial found none; the positive result belongs to the GHK-Cu and its carrier together. Larger studies (71 and 41 women, reported at a dermatology meeting in 2002) are known only through Pickart’s reviews; we found no full report. This is limited, mostly industry-linked evidence of a modest cosmetic effect.
- Wounds. The two ulcer trials disagree, and in the trial after laser the evaluators found no benefit.
- Hair. The only trial of GHK-Cu alone looked at eyebrows; its effect, fewer than two hairs per brow, sits at the edge of statistical significance. The one randomized scalp trial used a copper-free GHK compound, a different molecule.
The Pharmaceutics review, whose authors declare no conflicts, calls GHK-Cu “a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug”, and a 2026 review for orthopaedic and sports physicians says “no clinical data support its use for musculoskeletal conditions”.
Reported in people: mixtures, two of them given by needle
The other human reports had no comparison group and used a copper peptide among several ingredients, so none can show what it did by itself. Two gave the mixture by needle into the skin, the closest the human record comes to injection.
| Report | People | What was given | What was reported | Funding or limits |
|---|---|---|---|---|
| Kapoor and Shome, 2018 | 1,000 patients | A six-ingredient hair formulation (four growth factors, thymosin β4 and copper tripeptide-1) injected into the scalp skin | “Significant reduction in hair fall was seen in 83% of the patients on hair pull test”. “Treatment was well tolerated.” | The authors developed the formulation and hold a patent on it. Abstract only. |
| Kuceki, 2025 | 7 men | Minoxidil, dutasteride and “copper peptides” (type not stated) infused into the scalp through short needles | Median regrowth of the top of the scalp 26.5% (interquartile range 15.3% to 32.8%). No adverse reactions “such as scarring or infection”. | Retrospective. No funding; one author has advised companies. |
Four smaller reports (2016 to 2024) put a copper peptide on the skin among several ingredients; each described improvement, two with more collagen on biopsy.
Animal studies
These are animal findings, not evidence of what a serum or an injection does in a person.
- Wounds. In rats, GHK-Cu injected into wound chambers increased the build-up of connective tissue and collagen. The 2026 Pharmaceutics review calls acute-wound repair “the best-supported preclinical claim”.
- Lungs. Three mouse studies of GHK or GHK-Cu reported less lung injury or scarring; the same review rates this work “the strongest of this group” of body-wide claims.
- Joints and hair. In rats, GHK-Cu injected into a knee after ligament surgery “improved graft healing … but the beneficial effects could not last as treatment discontinued”. A 1991 mouse study from ProCyte, with Pickart among its authors, reported hair-follicle stimulation (title only; no abstract is available).
Lab studies and how it is thought to work
No mechanism has been shown in a study in people. What follows comes from chemistry and cells:
- Copper (chemistry and theory). GHK binds copper tightly and forms complexes with copper and albumin, a blood protein. A 2018 review by Pickart proposes that GHK-Cu acts by delivering copper to enzymes that need it; that is theory, not tested in people.
- Collagen (cells). In cultures of fibroblasts, the cells that make collagen, GHK-Cu stimulated collagen production at very low concentrations.
- Gene activity (computer analysis and cells). Two studies searched a public database of gene activity in cancer cell lines and found that GHK reversed patterns linked to the spread of colorectal cancer (2010) and to emphysema (2012); in the second, whose authors’ university holds intellectual property related to the work, GHK also “restored collagen I contraction and remodeling” in lung fibroblasts. The 2026 Pharmaceutics review says of these papers: “None of them establishes tissue exposure or clinical benefit in humans”.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No study has compared doses, so none can be called optimal.
Doses tested in people
Only on the skin:
| Study | Strength | How applied | How long |
|---|---|---|---|
| Bishop, 1992 | 0.4% cream (a “tripeptide copper complex”) | Not in abstract | Not in abstract |
| Mulder, 1994 | Gel in a “metered dose”; strength not in abstract | Daily | Not in abstract |
| Miller, 2006 | Not reported | Not in abstract | 12 weeks |
| Badenhorst, 2016 | Not stated | Face, twice daily | 8 weeks |
| Bo, 2026 | 2% serum | Eyebrow, twice daily | 12 weeks |
By injection, by mouth or by nose, no dose of GHK-Cu alone has been tested, and neither report of a mixture given by needle states its GHK-Cu amount.
Doses in common use
These are amounts in circulation: practice no trial set, given with their sources and what was studied.
- On the skin: 0.5%, 1% and 2% recur on one compounding pharmacy’s prescriber pages, and 0.5% on a second pharmacy’s page and a clinic’s blog, once or twice daily; ranges run from suppliers’ “0.05-1%” (a skincare brand’s ingredient reference) to “2 to 5%” (a seller’s page). Only 2% has a favourable trial behind it (eyebrows), and no study states a higher strength.
- In cosmetics: the Cosmetic Ingredient Review (an expert panel, not a government regulator) judged copper tripeptide-1 “safe in the present practices of use and concentration in cosmetics” in 2014, taking “< 10 ppm” (0.001%), from one industry submission, as the typical use concentration of the peptides it grouped together: at least 100 times below any strength a human study states. Its report records no use concentration for copper tripeptide-1 and no safety test of the peptide itself, and it assesses neither the stronger products above nor compounded medicines nor injection; the ingredient reference sets the verdict beside the suppliers’ range.
- Injected under the skin: around 1 to 2 mg per injection (ranges 0.5 to 3 mg), two or three times a week to once daily, in cycles of about 4 to 12 weeks (one page up to 16), on seven clinic, seller and online-protocol sites; none backed by a study in people.
- Other routes: 625 to 1,250 micrograms a day by nose and 2 mg a day by mouth, on one supplement seller’s product pages; neither has a study in people.
What the pharmacology supports, and what it doesn’t
- Amount. Measured in people: nothing. Inferred: repeated injection is where a copper build-up is most plausible: the 2026 Pharmaceutics review says dietary limits “cannot be converted directly into parenteral limits” [parenteral: by injection].
- Frequency and duration. Inferred from rats and lab tests: the injected peptide is probably short-lived, but its copper joins the body’s stores, so no interval follows. Convention: cycles with breaks; none has been tested.
- Route. Measured in the lab, not in people: how much gets through the skin is unsettled. One study found copper from a GHK-Cu solution crossing thinned human skin over 48 hours; another found “almost no peptide or copper permeated through intact human skin” in 9 hours, until microneedles pierced it. The two prepared the skin differently and can’t be compared directly. Not measured: what an injection delivers.
- Monitoring. Inferred: if copper could reach the bloodstream, blood copper and liver enzymes would be the logical checks, though the NIH says “no biomarkers that accurately and reliably assess copper status have been identified”.
Nobody knows what any injected amount does in people.
What common protocols get wrong
- One figure, no origin. None of the seven sites traces its injected figure to a study. One seller cites a single review (Pickart, 2018), which reports no injected dose in people.
- Miscited sources. A clinic’s page links its “4,000 human genes” claim to a paper on seizures after tranexamic acid. A pharmacy’s page says studies suggest hair growth “comparable to 5 % minoxidil”, citing the DOI of a spinal cord injury review; none of the human studies compares the two, and the only such comparison we found was in mice.
- Other evidence under an injection heading. One clinic’s article on injections claims “Multiple controlled studies” of hair growth, though we found no hair study of injected GHK-Cu alone; another rests its cycle on a rat wound study, which it does call animal work, and a skin review.
- Claims that cancel out. A clinic’s page says unbroken dosing “blunts receptor sensitivity”, while a seller’s page says GHK-Cu “doesn’t trigger the same kind of receptor desensitization”. The same clinic’s page says it “works by signaling, not by accumulation” and “depends on gradual tissue accumulation”. An online protocol lists “No established human dose”, then “recommended doses (1-3mg daily)”.
- Copper and the FDA. That protocol says “Your body handles this copper the same way it processes copper from food”, against the Pharmaceutics review on its source list, and gives a half-life of “Approximately 1 hour” with no source. A guide says “GHK-Cu is not on the FDA’s restricted peptide lists”; the FDA lists the injectable form with the concern quoted above.
For any prescribed medicine, the dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
On the skin. In the two trials that reported them, skin reactions were uncommon and minor. In the 40-woman trial the serum was “well tolerated by 39 of the 40 subjects”; one woman had “minor unwanted skin reactions” on both sides of her face, stopped, and recovered. The eyebrow trial reported “No serious adverse effects or allergic reactions” in 18 people, after excluding anyone who reacted to a patch test. The diabetic-ulcer trial recorded fewer infections with the gel (7% against 34%, in ulcers treated straight after dead tissue was removed). The other abstracts give no safety results. Copper “is a recognized contact sensitizer in susceptible individuals” [it can cause a skin allergy], the 2026 Pharmaceutics review notes.
Injected on its own. There are no side-effect data, because there is no study. What exists is the FDA’s statement above, three recalls (below), and a news report: in September 2026, NPR quoted a clinician who says he sees raised liver enzymes and copper in people who inject it themselves. NPR added that “it’s unclear whether copper peptides, or some other undisclosed substances or impurities are responsible”, and that he offers GHK-Cu himself. We found no published case report.
Theory. On theory alone, people with cancer or a history of it, proliferative retinopathy or a blood-vessel malformation have most reason for caution: GHK-Cu promotes blood-vessel growth in animal and cell studies, and the 2026 Pharmaceutics review says uses that rely on this “should explicitly consider malignancy, proliferative retinopathy, and vascular malformation as contexts requiring heightened caution”. There are no data in people. Free copper can also promote oxidation.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy, breastfeeding, under 18 | No data in people. | No study included these groups |
| Wilson disease or another copper disorder | Not studied. Avoiding added copper is a reasonable inference, not a finding. | NIH: people with Wilson’s disease “have a high risk of copper toxicity” |
| Other medicines | “Copper is not known to have any clinically relevant interactions with medications” (NIH). In theory, a copper source would oppose copper-lowering treatment. | NIH copper fact sheet; reasoning |
| With other peptides | No study of GHK-Cu blended with BPC-157 and TB-500, with or without KPV, was found. | PubMed and ClinicalTrials.gov searches |
Product quality
We found no published analysis of the GHK-Cu products sold online for “research use only”. That absence is not reassurance.
The FDA’s enforcement reports, read on November 18, 2026, list three recalls of compounded GHK-Cu injections, all Class II: two for “Lack of Assurance of Sterility” (reported in December 2020 and October 2025) and one for “Lack of Processing Controls” (reported in November 2026).
“GHK-Cu” is also not one fixed substance: PubChem, the public chemical database, lists a form with one copper per peptide (about 15.8% copper by weight), the wound gel’s form with two peptides per copper (about 7.4%), and different salts. A product’s copper content can’t be assumed from its name (our inference).
What we make of it
This section is our reading of the evidence: judgment, not a finding.
On the skin, GHK-Cu is a cosmetic ingredient with limited, mixed trial evidence, and a modest cosmetic effect is plausible. The cell and animal work gives a reason to expect one, one controlled trial found one, and the trials recorded few skin reactions. What holds us back from saying more: that trial was maker-funded and tested the peptide together with its carrier, the other trial’s evaluators found no difference, and lab studies leave open how much passes through intact skin. For wounds, the two ulcer trials in people disagree.
By injection, GHK-Cu is unproven and experimental, and the claims have run far ahead of the evidence. An absence of studies is not evidence of no effect, and injected GHK-Cu may yet turn out to be useful. But for the claims to hold, three things would have to be true that nobody has measured: that the injected peptide lasts long enough to act, though in rat blood and in human plasma in the lab it breaks down quickly; that the gene changes seen in cancer cell lines happen in human tissue and improve health; and that repeated doses of injected copper do no harm. Against that sit the FDA’s stated concern, three recalls and no safety data in people for GHK-Cu injected on its own. On present evidence we can’t tell a patient what it will do for them, or to them.
Whether GHK-Cu has a place in anyone’s care, for whom, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
At Rock Creek Wellness (RCW), peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which; you don’t choose one from a menu. Our peptide therapy page explains how that care is set up and what it costs.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A study of injected GHK-Cu in people: how long it lasts, what it does to copper levels, and its side effects. We found none, published or registered.
- The results of trial NCT07437586 (Hudson Biotech): a phase 2, randomized, masked trial planned for 60 healthy adults, comparing a 0.1% GHK-Cu gel with its base on punch wounds. Primary completion is estimated for February 14, 2027; no results are posted.
- The FDA’s advisory committee meeting, expected before the end of February 2027 (no date set when this status was checked), and any decision that follows on the 503A bulks list.
Common questions
Does GHK-Cu work for wrinkles?
On the skin, possibly and modestly; the evidence is thin. One maker-funded trial found smaller wrinkles after eight weeks of a GHK-Cu serum, and the evaluators in a very small trial after laser resurfacing found no difference. Injections have not been tested.
Does GHK-Cu regrow hair?
It has not been tested on its own for scalp hair loss. The one trial of GHK-Cu alone tested a serum on the eyebrows of 18 people and found fewer than two extra hairs on the treated side. The scalp studies used mixtures or a copper-free compound.
Is a copper peptide serum the same as a GHK-Cu injection?
No. A serum sold only for appearance is regulated as a cosmetic and has a small record of trials on the skin. Injected on its own, GHK-Cu has no study in people, and the FDA has stated a safety concern about compounded injections.
How much is used, and how often?
On the skin, only two trials state a strength: 0.4% in an ulcer trial that found no benefit, and a 2% serum twice daily for 12 weeks on eyebrows. No amount of injected GHK-Cu alone has been tested in anyone. Pharmacies’ prescriber pages, clinics, an ingredient reference and sellers together list 0.05% to 5% on the skin and around 1 to 2 mg per injection, two or three times a week to once daily: practice no trial set. How often any dose would have to be given is unknown.
Is GHK-Cu FDA-approved?
No. No form of GHK-Cu is an FDA-approved drug. A serum sold only for appearance is a cosmetic, which needs no FDA approval before it goes on sale, and the wound gel cleared in 1996 is a device, not an approved drug.
Can a doctor prescribe GHK-Cu?
The federal sources we read give no yes or no about prescribing: their conditions attach to the compounding and to the product, not to the act of writing a prescription. GHK-Cu is not an FDA-approved drug, so a prescription could only be for a compounded medicine. The FDA’s position on compounding each form, which is not approval, and the Kansas rule are set out above.
Sources
Show all 61 sourcesHide sources
- Prezatide copper (copper tripeptide-1), CID 71587328. PubChem, NCBI, 2026.
- Prezatide copper acetate (Iamin), CID 9876021. PubChem, NCBI, 2026.
- Glycyl-L-histidyl-L-lysine (GHK), CID 73587. PubChem, NCBI, 2026.
- Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology, 1973.
- Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia, 1977.
- Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (categories list, Updated May 14, 2026). FDA, 2026.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA, 2025.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA, 2026.
- Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027). FDA, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, 2026.
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). FDA, 2024.
- Warning Letter: Tailor Made Compounding LLC, MARCS-CMS 594743. FDA, 2020.
- Drug recall enforcement reports for GHK-Cu (D-0141-2021, D-0051-2026, D-0129-2027). FDA Enforcement Report via openFDA, 2020-2026.
- 510(k) K953853: IAMIN Gel Wound Dressing, ProCyte Corp.. FDA, 1996.
- World Anti-Doping Code International Standard: Prohibited List 2026. WADA, 2025.
- Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. WADA, 2026.
- A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery, 1992.
- Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration, 1994.
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006.
- Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science, 2016.
- The Efficacy of 2% Copper Peptide (GHK-Cu) Serum for Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled, Split-Face Comparative Study. Procedia of Multidisciplinary Research, 2026.
- Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology, 2016.
- Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy, 2018.
- QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. Plastic and Reconstructive Surgery Global Open, 2020.
- Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD International, 2025.
- Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. Journal of Cosmetic and Laser Therapy, 2018.
- Significant improvement in crow’s feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation). Journal of Cosmetic and Laser Therapy, 2016.
- The effects of hydroporation on melasma with anti-aging cocktail. Journal of Cosmetic Dermatology, 2017.
- An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults. Cureus, 2024.
- Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586). ClinicalTrials.gov, 2026.
- GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 2026.
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthetic Surgery Journal, 2026.
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts, 2025.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026.
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018.
- GHK and DNA: Resetting the Human Genome to Health. BioMed Research International, 2014.
- In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993.
- GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition. Frontiers in Pharmacology, 2017.
- The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget, 2016.
- The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology, 2024.
- Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research, 2015.
- The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Annals of the New York Academy of Sciences, 1991.
- The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 2007.
- Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorganic Chemistry, 2021.
- A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical & Experimental Metastasis, 2010.
- A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 2012.
- Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research, 2010.
- Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research, 2015.
- Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. Journal of Chromatography B, 1997.
- H-Gly-His psi(NHCO)Lys-OH, partially modified retro-inverso analogue of the growth factor glycyl-L-histidyl-L-lysine with enhanced enzymatic stability. International Journal of Peptide and Protein Research, 1993.
- Copper: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements, 2022.
- People are injecting copper peptides ahead of the science. NPR, 2026.
- Clinical assessment of a combination lip treatment to restore moisturization and fullness. Journal of Clinical and Aesthetic Dermatology, 2009.
- Permeation behaviour of cosmetic actives into the human stratum corneum. International Journal of Pharmaceutics, 2026.
- K.A.R. 68-13-3, Nonsterile preparations. Kansas Secretary of State, 2018.
- Board of Pharmacy, Reports & Guidance Docs. Kansas Board of Pharmacy, 2026.
- Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics (Final Report, release date June 30, 2014). Cosmetic Ingredient Review, 2014.
